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Abstract
Background & Aims: Mixed cryoglobulinaemia (MC) is an HCV-related lym-
phoproliferative disorder characterized by the presence of circulating
immune complexes called cryoglobulins. Treatment with anti-CD20 mono-
clonal antibody rituximab is proved to be very useful, especially in patients
ineligible to interferon-based antiviral therapy. Recently, free light chain
(FLC) j/k ratio and FLC patterns were associated with MC. The aim of this
study was to evaluate changes in FLC-j, FCL-k, FLC ratio following ritux-
imab treatment in patients with HCV-related MC and to correlate FLC-j,
FCL-k and FLC ratio values with therapy response. Patients and Meth-
ods: We retrospectively enrolled 46 patients with HCV infection (26 females,
20 males), including 10 patients without signs/symptoms of MC-related vas-
culitis, 36 with MC vasculitis. Clinical and biological data were recorded at
baseline and 6 months after RTX treatment. Nephelometric measurement of
serum FLCs was taken. Results: The mean serum FLC-j level and FLC ratio
were significantly higher in patients with MC, compared to HCV patients
without MC and to blood donors. An abnormal FLC ratio at baseline corre-
lated with the presence of cryoglobulins, C4 consumption, higher RF level
and higher vasculitis rate. To evaluate the predictive value of FLCs, patients
with MC were divided into two groups according to RTX therapy outcome
(responders and no/partial responders). Abnormal baseline FLC ratio was
significantly associated with no/partial response. Conclusions: RTX treat-
ment in HCV-related MC induces a reduction in FLC-j and RF levels. More-
over, pretreatment FLC ratio, which can be easily assessed by a routine test,
may be useful to predict response to this expensive treatment for patients
with HCV-related MC ineligible to IFN-based therapy.
Mixed cryoglobulinaemia (MC) is the most frequent,
best known and strictly hepatitis C virus (HCV)-associ-
ated extrahepatic manifestation: in Italy, more than 90%
of patients with MC are HCV positive (1, 2). MC is both
an autoimmune and B-lymphoproliferative disorder
(LPD), clinically benign but evolving to a frank malig-
nancy in about 8–10% of cases (2, 3).
Mixed cryoglobulinaemia is characterized by intravas-
cular immune complexes – the so-called cryoglobulins
(CGs) – composed of IgGs and IgMs. The IgM has rheu-
matoid factor (RF) activity and is produced by clonally
expanded autoreactive B cells (4, 5). The clinical manifes-
tations of MC are attributable to a systemic vasculitis
caused by the intravascular CGs and can be classified as
one of the immune complex-mediated systemic vasculi-
tis, involving small- to medium-sized vessels. Meltzer
et al. (6) firstly described MC as a triad of purpura, fati-
gue and arthralgia. The different symptoms arise from
the involvement of various organs and systems, namely
skin, joints, kidney, nervous system, salivary and lachry-
mal glands (6–8). Hence, the symptoms defining a full-
blown MC can be so multiple and severe to determine a
very poor quality of life for the patient (6–8).
Although antiviral therapy has been indicated as first-
line therapy in patients with mild-to-moderate HCV-
related MC vasculitis (9), in severe cases, or in patients
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intolerant/ineligible to antiviral therapy, anti-CD20
monoclonal antibody rituximab (RTX) should be con-
sidered (10–12).
Serum free light chains (FLCs), j and k, have been
identified as useful markers whose alteration is linked to
specific diseases; the quantitative assay of j chains, k
chains and j/k FLC ratio is a useful diagnostic tool in
plasma cell dyscrasias, such as multiple myeloma,
monoclonal gammopathy of undetermined significance
and amyloidosis (13–19).
Furthermore, an abnormal j/k FLC ratio is inter-
preted as a surrogate for clonal expansion (20–22). The
fast turnover of FLC, particularly true for the k chain
(<6 h compared to 20–25 days to total IgG), explains
that they may be considered ideal markers of response
in patients undergoing RTX treatment.
Recently, an altered j/k FLC ratio and FLC patterns
were associated with the presence of MC vasculitis and/
or B-NHL in HCV-positive patients (23, 24). The same
authors also suggested that serum FLC ratio could be
used as a surrogate marker for HCV-related lymphopro-
liferation after IFN-based antiviral therapy (23).
To date, there are no reports in the literature con-
cerning changes in j and k FLC and j/k FLC ratio after
administration of RTX in MC subjects.
The aim of this study was therefore to evaluate pre-
and post-treatment j and k FLC serum values and j/k
FLC ratio levels in a cohort of patients with severe
HCV-related MC vasculitis treated with RTX, due to




Forty-six patients with HCV infection (26 F, 20 M,
mean age 59.25 ± 9.48) were retrospectively enrolled at
the MaSVE Center (Center for Systemic Manifestations
of Hepatitis Viruses) outpatient clinic (University of
Florence, Florence, Italy), including 10 patients without
signs/symptoms of MC-related vasculitis (pathological
controls), 36 with MC vasculitis of which 3 affected by
B-cell non-Hodgkin lymphoma (B-NHL). We also
enrolled 50 healthy blood donors (as controls) whom
had previously been tested for the absence of monoclo-
nal components (by serum protein electrophoresis,
serum and urine immunofixation).
Concerning the cohort of patients with MC, FLC
assessment was performed using serum samples collected
at baseline and 6 months after RTX treatment (immedi-
ately stored at 80°C). For the pathological control
group, we used serum samples that were immediately
stored at 80°C following collection from patients with
active chronic HCV infection without signs and symp-
toms of MC (or other autoimmune/lymphoproliferative
disorders) and who had not received any antiviral treat-
ment for at least 6 months prior blood collection.
The criteria for the diagnosis of MC vasculitis have
been previously described (10, 12). Serum cryoglobulin
levels and characterization, levels of complement frac-
tions, rheumatoid factor and autoantibodies were evalu-
ated as described (25, 26).
The diagnosis of liver disease was performed accord-
ing to histological and/or clinical and ultrasound exami-
nation (27–29).
Patients with MC vasculitis enrolled in the study were
not suitable for antiviral treatment, due to contraindica-
tions or poor tolerance. Inclusion criteria for RTX
administration were the presence of HCV-positive MC
syndrome with advanced chronic liver disease. Exclu-
sion criteria were all known causes of chronic liver dis-
ease other than HCV infection, with particular attention
to the presence of hepatitis B surface antigen and anti-
HIV antibodies.
Administration of RTX was performed according to
the following regimen: first intravenous infusion of 1 g
RTX at day 0 and second perfusion of 1 g RTX at day
15. Prior to infusion, the patients received a premedica-
tion consisting of acetaminophen, dexchlorpheniramine
maleate and allopurinol. The concomitant use of high-
dose steroids would be only allowed in case of hypersen-
sitivity. Following RTX treatment, patients with MC
were divided into two groups on the basis of clinical
response to therapy: patients with a complete response
and patients with no/partial response, according to Petr-
arca et al. (12).
All patients included in this study provided written
informed consent in accordance with the principles of
the Declaration of Helsinki and the study was approved
by the University of Florence Ethical Committee.
Serum FLC assessment
Nephelometric measurement of serum FLCs in stored
samples was taken by means of N Latex FLC-kappa and
FLC-lambda kits (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany), an assay that
Key points
• No tools are available to predict response to RTX
in patients with severe MC.
• A reliable outcome predictor is fundamental for a
rational management of a more tailored therapy.
• As the latest guidelines for the new antiviral thera-
pies indicated MC as a priority condition to treat, an
additional routine test, such as the FLC dosage, useful
to assess a certain diagnosis of MC, could be a new
tool to identify patients who need an urgent access to
antivirals.
• For patients ineligible to antivirals, FLC assay may
be a predictive diagnostic tool to overcome decisions
concerning RTX treatment of HCV-related MC vas-
culitis.
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employs monoclonal antibodies directed against FLCs
for their quantification.
As pioneer of the field, the FLC assay showed poor
post-dilution linearity and relative imprecision, as well
as increased probability of yielding false-negative results
due to antigen excess in patients with extremely high
FLC concentration. N Latex assay by Siemens, based on
monoclonal antibodies and recently introduced on the
European market, is demonstrated to overcome part of
these problems.
Measurements were taken according to the manufac-
turer’s protocol on the BNII automated analyzer,
the lowest detection limit for j and k FLCs being
0.035 mg/L. Calibrators and controls were provided by
the manufacturer and consisted of stabilized human sera
containing polyclonal j and k FLCs; calibrators and
controls were diluted to the appropriate concentrations
for serum determinations, following the manufacturer’s
instructions.
The analysis was performed by an operator without
knowledge of the clinical information of the handled
sample. Each sample was tested twice to minimize even-
tual discrepancies, and all tests were performed in the
same laboratory with the same instrument. All safety
precautions were taken while handling potentially
harmful samples.
Statistical analysis
Data are expressed as mean ± standard deviation. The
numerical comparison of continuous data was made
using Student’s t-test for paired samples. Statistical sig-
nificance was set at a value of P < 0.05. The chi-square
test was used to evaluate categorical variables. To assess
the value of FLC-K, FCL-k and FLC ratio as predictors
of response to therapy, the 36 patients enrolled were
divided into two groups according to clinical response
to treatment. Predictive values were determined by cal-
culating odds ratio (OR).
Statistical analysis was computed using STATA 12 soft-
ware (Stata Corporation, College Station, TX, USA).
Results
The main baseline characteristics of the study popula-
tion with chronic HCV infection (26 F, 20 M, mean age
59.25 ± 9.48 years) are reported in Table 1.
FLC-j, FCL- k and FLC ratio were retrospectively
measured in 46 HCV patients and in 50 blood donors.
The mean serum j FLC level was significantly higher
in HCV-positive patients with MC vasculitis
(34.76 ± 26.65 mg/L) than in patients without MC
(17.51 ± 9.29 mg/L) and in blood donors
(13.22 ± 5.31 mg/L) (P = 0.05 and P < 0.0001 respec-
tively) (Fig. 1A).
The mean serum k FLC levels were alike in patients
with MC vasculitis, without MC and in blood donors
(Fig. 1B).
The mean FLC ratio was higher in MC vasculitis
(2.35 ± 1.11 mg/L) than in patients without MC
(1.072 ± 0.22 mg/L) and in blood donors
(0.81 ± 0.24 mg/L) (P = 0.0023 and P = 0.0008 respec-
tively) (Fig. 1C).
Patients were analysed according to FLC ratio values,
and the whole population was virtually divided in sub-
jects with normal ratio (≤1.56) and with abnormal ratio
(>1.56). An abnormal FLC ratio correlated with the
presence of CGs (P = 0.000) and was also associated
with a higher mean cryocrit value, although statistical
significance was not reached.
Patients with abnormal FLC ratio also showed a more
frequent C4 consumption and higher RF levels
(P < 0.005 for both parameters), higher MC vasculitis
rate (P = 0.000) and higher rate of Meltzer and Franklin
triade (purpura 88%, arthralgia 83% and asthenia 79%,
P = 0.004, P = 0.027 and P = 0.031 respectively).
An involvement of the peripheral nervous system was
also more frequent in the group of subjects with abnor-
mal FLC ratio (P = 0.0021) as opposed to patients with
an FLC ratio in the normal range.
Patients affected by vasculitis underwent RTX treat-
ment and were divided in two subgroups according to
the therapy outcome: patients with a complete clinical
response (CR, n = 15) and patients with partial/no
response (PNR, n = 21).
The statistical analysis of the mean pre- and post-
therapy levels of j, k and FLC ratio among CR patients
and among PNR patients did not reveal any significant
difference (Table 2) as well as the comparison of the
pre- and post-treatment mean values between the two
response groups (Table 3). Considering the number of
patients with an abnormal FLC ratio (>1.56) at baseline,
this was significantly higher in the PNR compared to
CR group (P = 0.0314).
When we considered the risk of clinical non-response
to treatment, only abnormal baseline FLC ratio was signif-
icantly associated with no/partial response (P = 0.0314)
with an OR of 4.86 (95% CI 0.89–28.72). This result was
also confirmed by multivariate analysis: indeed, abnormal
FLC ratio at baseline emerged as the only independent
predictive factor of no/partial response to RTX treatment
(OR 7.7–95% CI 1.17–51.06–P = 0.034).
These findings are very interesting because, as previ-
ously mentioned, no tools are currently available to help
clinicians predict response to RTX administration in
patients with severe MC vasculitis.
Discussion
From a retrospective analysis of patients with chronic
HCV infection, either with MC vasculitis or without
MC, we found elevated serum levels of FLC-j and FLC
ratio in patients with MC vasculitis as opposed to both
the HCV-positive subjects without signs/symptoms
of lymphoproliferative disorders and the 50 healthy
control subjects. These results completely confirm previ-
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ous observations (23), suggesting a role for these serum
proteins as markers of HCV-related MC vasculitis.
As expected, other classical serum parameters of MC,
namely RF and C4, were found to be altered in the HCV
MC group compared to controls.
The correlations between an abnormal ratio (>1.56)
and presence of circulating CGs, C4 consumption,
higher RF levels, higher MC vasculitis rate, higher rate
of Meltzer and Franklin triade and the involvement of
peripheral nervous system clearly confirm the role of
this parameter as serum biomarker of disease activity.
All the patients with MC vasculitis were treated with
RTX due to their ineligibility to IFN-based antiviral
treatment [now recommended as the first therapeutic
option for HCV-related MC in the absence of contrain-
dications (9)] or owing to failure of previous aetiologi-
cal therapies.
All the serum parameters tested at baseline were eval-
uated after 6 months of follow-up, when the B-cell pop-
ulation is considered to be restored.
Among the patients with MC treated with RTX, no
statistically significant differences on the mean values of
j, k and FLC ratio were evident, between the CR and
NPR groups, either at baseline or after 6 months. Nota-
bly, 6 months after RTX infusions, in the CR group,
eight patients showed an abnormal ratio, while before
Table 1. Main baseline characteristic of the 46 HCV-positive patients, according to the results of FLC ratio
All patients (n = 46) Normal FLC ratio (n = 22) Abnormal FLC ratio (n = 24) P value
Mean age (years) 59.25 ± 9.48 57.16 ± 9.22 61.14 ± 9.53 0.1578
Sex (male/female) 20/26 14/8 6/18 0.016
HCV genotype
1 (%) 32 16 16 0.55
2 (%) 7 2 5 0.42
3 (%) 6 4 2 0.41
4 (%) 1 – 1 1.00
Histology
Chronic Hepatitis (%) 25 (54) 9 (40.9) 16 (66.7) 0.138
Cirrhosis (%) 21 (46) 13 (59.1) 8 (33.3)
ALT (ULN) 1.5 ± 1.14 2.23 ± 1.23 1.19 ± 1.17 0.0052
Viral titre (IU/ml 9106) 3.28 ± 3.5 3.1 ± 3.9 3.4 ± 3.2 0.7761
Characteristics of MC
No MC 10/46 (22%) 10/22 (45%) 0/24 (0%) 0.000
MCS 36/46 (78%) 12/22 (55%) 24/24 (100%) 0.000
MCS with B-NHL 3 0 3
MCS without B-NHL 33 12 21
Characteristics of MC
Positive cryocrit 36/46 (78%) 12/22 (54.5%) 24/24 (100%) 0.000
Cryocrit % 7.11 ± 9.71 3.21 ± 2.35 9.06 ± 11.36 0.0886
Type II 23/36 (64%) 8/12 (67%) 15/24 (62.5%) 1.000
Type III 6/36 (17%) 3/12 (25%) 3/24 (12.5%) 0.378
Type nd 7/36 (19%) 1/12 (8%) 6/24 (25%) NR
C4 consumption 18/46 (39%) 5/22 (23%) 13/24 (54%) 0.0038
RF alteration 30/46 (65%) 9/22 (41%) 21/24 (88%) 0.002
MC vasculitis symptoms
Purpura 31/46 (67%) 10/22 (45%) 21/24 (88%) 0.004
Arthralgia 31/46 (67%) 11/22 (50%) 20/24 (83%) 0.027
Asthenia 29/46 (63%) 10/22 (45%) 19/24 (79%) 0.031
Sicca Syndrome 21/46 (46%) 7/22 (32%) 14/24 (58%) 0.085
Raynaud phenomenon 14/46 (30%) 4/22 (18%) 10/24 (42%) 0.114
Peripheral neuropathy 33/46 (72%) 12/22 (55%) 21/24 (88%) 0.021
Renal involvement 9/46 (20%) 2/22 (9%) 7/24 (29%) 0.139
Ulcers 11/46 (24%) 4/22 (18%) 7/24 (29%) 0.497
Serum FLC assessment
j 30.45 ± 24.60 17.01 ± 13.73 42.61 ± 26.14 0.002
k 16.75 ± 14.78 17.20 ± 17.25 16.34 ± 12.56 0.8467
FLC ratio 2.03 ± 1.18 1.06 ± 0.22 2.91 ± 0.83 0.0000
Bold values denote significant values.
Values are expressed as mean ± standard deviation.
ALT, alanine aminotransferase; ULN, upper limit of normal; IU, international units; nd, not determined.
FLC-j, normal values: 6.7–22.4 mg/L; FLC-k, normal values: 8.3–27 mg/L; FLC ratio, normal values: 0.31–1.56.
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the treatment one patient less had an abnormal ratio.
The number of CR patients with abnormal j FLC pre-
and post-treatment did not change.
These observations apparently seem in contrast to the
role of biomarkers of disease previously attributed to j
FLCs and FLC ratio for HCV-related MC vasculitis.
Indeed, some authors reported a paradoxical increase of
serum FLC concentrations in multiple myeloma treated
with different drugs (30). As the effect of RTX is transi-
tory, it is possible to hypothesize an occurring rebound
effect during B-cell repopulation also in patients who
achieved complete response to therapy.
In fact, a limitation of our analysis is due to its retro-
spective nature that restricted the study time points on
the basis of biological samples available in the MaSVE
Center bio-bank.
Further prospective studies will be useful to follow, in
parallel, the behaviour of j and k FLC and their ratio, at
different time points during the 6 months in which the
B-cell compartment undergoes depletion and is subse-
quently followed by its slow restoration. This will allow
a better understanding of the prognostic meaning of the
FLCs in the free-from-disease period.
Nowadays, RTX treatment is considered effective and
safe, especially in those cases of HCV-related MC vascu-
litis either who are ineligible for antiviral treatment or
who previously failed such option. However, due to the
elevated costs of RTX therapy, a correct evaluation of
patients that most likely will accomplish complete
response to therapy could help avoid a waste of
resources, as well as spare patients from undergoing
ineffective drug treatment options unsuitable for their
characteristics and from side effects that, albeit rare,
may still occur (i.e. hyperviscosity syndrome).
To date, a variety of predictive markers of response
to RTX treatment, ranging from circulating serum
proteins to genetic factors, have been proposed for dif-
ferent rheumatic diseases. For example, in rheumatoid
arthritis, RF levels influenced the outcome of RTX treat-
ment (31) and the anti-CCP positivity was a predictor
of good to moderate response, while high Ig levels were
associated with a worse outcome (32). Also, a specific
host genetic background seems to have a role in deter-
mining the clinical outcome following RTX infusion.
Fabris and coworkers showed that CC homozygosis of
the 174G/C interleukin-6 (IL-6) polymorphism is
linked to a lower efficacy of this treatment in patients
with rheumatoid arthritis (33). The only data regarding
HCV-related MC and the issue of predictors of response
to RTX are reported in a study by Gragnani et al. (34)
in which a particular genetic variant of Fcc receptor IIIA
seems to be crucial to determine the anti-CD20 effec-
tiveness.
In spite of the expectations concerning the application
of these results to the clinical practice, no tools are yet
available for clinicians to help them in decision-making
when choosing the most appropriate individualized tar-
geted therapy, possibly due to the fact that all the above-
mentioned markers still require setting-up as routine tests.
In this context, FLC nephelometric determination
may be of diagnostic aid to overcome decisions con-
cerning therapeutic treatment schemes in the light of
what stated above.
Free light chains are involved in antigen recognition
and binding to same extent as the intact immunoglobu-
lins, thus contributing to the development of antibody-
specific affinity. The specific properties that link FLCs to
the activation of mast cells responsible of inducing the
pathogenic mechanisms of diseases characterized by
chronic inflammation has raised great interest on their
Blood donors HCV MC-vasculitis
Blood donors HCV MC-vasculitis
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Fig. 1. Serum free light chain (FLC)-k (A), serum FLC-l levels (B) and
serum FLC ratio (C) in blood donors, in patients infected with hepa-
titis C virus without any signs and/or symptoms of mixed cryoglobu-
linaemia (HCV) and in patients with mixed cryoglobulinaemia (MC)
vasculitis.
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clinical use, both as challenging ‘target’ and as therapeu-
tic marker of biochemical progression or remission of
the disease. Indeed, the clinical interest for the determi-
nation of FLC in patients infected with human immu-
nodeficiency virus (HIV) or hepatitis C virus (HCV)
was reached based on the observations that an increased
concentration of FLCs in these diseases may be consid-
ered as biomarker for early onset of neoplasia, in partic-
ular of lymphoma (35).
The development of serum assays for free FLC-j and
FLC-k has opened the door to new applications increas-
ing their clinical importance beyond monoclonal
gammopathies and plasma cell dyscrasias. In particular,
the availability of these tests may open new perspectives
for diagnosing and managing various diseases character-
ized by chronic inflammation (36).
For most of these diseases, serum polyclonal FLC
concentrations correlate with disease activity, therefore
constituting a potentially valuable tool for adjusting
therapeutic regimens.
Furthermore, the FLC assay is a routine test which
enables easy performance before RTX infusion to select
patients with greater chances of success. At the same
time, subjects who stand less chances of being complete
responders could be addressed towards other therapies.
The availability of reliable outcome predictors is funda-
mental for a more rational management of economic
resources and for a more tailored therapy.
On the other hand, the importance of the extrahe-
patic manifestations of HCV is nowadays officially rec-
ognized and the latest AASLD guidelines for the new
direct acting antivirals (DAA) indicated the MC among
the highest priority conditions to treat because of the
risk for severe complications (37). Therefore, the avail-
ability of an additional routine test, such as the FLC
dosage, useful to assess a diagnosis of MC, could be a
new tool to identify patients who need an urgent access
to antiviral treatment. Also, in the era of the new highly
effective DAA, the availability of this non-invasive
test could be precious to assess the effective control
of HCV-related lymphoproliferations after viral
eradication.
Furthermore, the low cost of the FLC assay (the price
is comparable to the other routine tests currently used
as autoimmunity markers) represents an additional
positive feature.
Further prospective studies conducted on wider
cohorts of patients performed by monitoring serum
FLC levels at different time points after RTX admin-
istration will help to set up a new prognostic test
useful for predicting therapy outcome in patients
affected by HCV-related MC vasculitis and to under-
stand how FLC levels follow the timing of B-cell
repopulation.
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Table 2. Statistical analysis of the mean pre- and post-therapy levels of j, k and FLC ratio among patients with complete response and
among patients with partial/no response to RTX treatment
Patients with complete response (n = 15) Pretherapy Post-therapy P value
FLC-kappa pretherapy 29.54 ± 29.74 29.41 ± 29.11 0.9904
FLC-lambda pretherapy 17.95 ± 22.70 17.53 ± 24.14 0.9612
FLC ratio pretherapy 2.02 ± 1.01 2.23 ± 1.02 0.5755
Patients with partial/no response (n = 21) Pretherapy Post-therapy P value
FLC-kappa post-therapy 38.24 ± 24.64 39.49 ± 27.45 0.8774
FLC-lambda post-therapy 16.13 ± 11.35 15.61 ± 14.20 0.8964
FLC ratio post-therapy 2.57 ± 1.15 3.26 ± 2.29 0.2244







(n = 21) P value
FLC-kappa pretreatment 29.54 ± 29.74 38.24 ± 24.64 0.3447
FLC-lambda pretreatment 17.95 ± 22.70 16.13 ± 11.35 0.7530
FLC ratio pretreatment 2.02 ± 1.01 2.57 ± 1.15 0.1464
FLC-kappa post-treatment 29.41 ± 29.11 39.49 ± 27.45 0.2969
FLC-lambda post-treatment 17.53 ± 24.14 15.61 ± 14.20 0.7661
FLC ratio post-treatment 2.23 ± 1.02 3.26 ± 2.29 0.1133
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